Conference: 2017 PH Professional Network Symposium
Release Date: 10.06.2017
Presentation Type: Abstracts
File Download: 2017 PHPN Abstract 1014
Download Adobe Acrobat
Abstract presented at the 2017 PH Professional Network Symposium held in Bethesda, MD on October 5-7, 2017
Evaluation of our patients transitioned from subcutaneous (SQ) treprostinil to intravenous (IV) treprostinil.
Pulmonary Arterial Hypertension (PAH) is a devastating disease with multiple therapy options. Several prostacyclin therapy options are available depending on the patient’s PAH etiology, disease severity, and preference. We report our single-center experience transitioning patients with PAH from subcutaneous (SQ) treprostinil to intravenous (IV) treprostinil.
We retrospectively reviewed charts of patients transitioned from SQ treprostinil to IV treprostinil from April 2010 through September 2015.
A total of 4 patients (mean age 44 years [range 32-56], 4 females) with PAH (1 idiopathic, 1 collagen vascular disease, 1 congenital heart disease, 1 portal hypertension) transitioned from SQ treprostinil to IV treprostinil. Of the 4 patients transitioned, 3 were due to site pain and 1 due to need for higher prostacyclin dosing because of declining status. Average dose of SQ treprostinil before transition was 49.3 ng [range 15-100 ng] and average dose of IV treprostinil after transition was 37 ng [range 8-78 ng]. After transition, the site pain resolved in 3 patients experiencing it. The one patient transitioned due to declining status has improved to an NYHA class II on IV treprostinil.
In this small case series we were able to demonstrate that patients can safely transition from SQ treprostinil to IV treprostinil. IV treprostinil can be an alternative parenteral prostacyclin therapy if patients are experiencing site pain from SQ treprostinil. The one patient with a declining functional status improved once transitioned to IV treprostinil. IV treprostinil can be a safe and beneficial alternative to SQ treprostinil. It provided relief from site pain in multiple patients and provided higher prostacyclin dosing to improve the functional status of one patient. Further study is required to validate these benefits in larger populations.